Compare Old Dominion Freight Line Inc (ODFL) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Old Dominion Freight Line Inc vs Recursion Pharmaceuticals Inc — how do they compare? Old Dominion Freight Line Inc trades at $180.01 (market cap $37.68B), while Recursion Pharmaceuticals Inc trades at $4.22 (market cap $2.14B). The key difference: Old Dominion Freight Line Inc is far larger — about 17.6× Recursion Pharmaceuticals Inc's market cap, and Old Dominion Freight Line Inc pays a 0.64% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Old Dominion Freight Line Inc for 76 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| ODFL | RXRX | |
|---|---|---|
Market Cap | $37.68B | $2.14B |
Volume | 1,550,104 | 30,789,535 |
Sector | Industrials | Health |
52-Week High | $248.73 | $6.79 |
52-Week Low | $126.29 | $2.84 |
Typical Hold Time | 76 Days | 22 Days |
Enterprise Value | $37.42B | $1.66B |
Dividend Yield | 0.64% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ODFL trades at $175.61, down 1.35% on the day, with a bearish technical signal but strong fundamentals including a 19.44% net income margin and consistent earnings beats. The company recently announced a 4.9% general rate increase effective October 5, 2026, to offset rising costs and support service investments. Despite a high P/E ratio of 34.95, robust profitability and positive cash flow trends underpin the stock's valuation.
The outlook is mixed: analyst consensus is a buy with a $230.93 price target, implying significant upside, but near-term technical pressure and valuation concerns present risks. Key catalysts include execution of the rate increase and Q3 2026 earnings, while macroeconomic pressures on freight demand remain a headwind.
RXRX trades at $4.05, down 5.15% today, with a bullish technical signal from moving averages. The company reported revenue of $74.26M in 2025 but a net loss of $644.76M, with negative profit margins. Recent news highlights strategic AI partnerships, including an extended data license with Tempus AI, aiming to fuel long-term growth despite current financial challenges.
The outlook remains speculative; the stock offers exposure to AI-driven drug discovery through a growing pipeline and partnerships, but high cash burn and lack of profitability pose significant risks. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for future catalysts tempered by near-term financial weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Old Dominion Freight Line Inc
Old Dominion Freight Line is the fourth-largest less-than-truckload carrier in the United States, with more than 240 service centers and 9,200-plus tractors. OD is by far one of the most disciplined and efficient providers in the trucking industry, and its profitability and capital returns stand head and shoulders above its peers. Strategic initiatives revolve around increasing network density through market share gains and maintaining industry-leading service via consistent infrastructure investment.
Read more on ODFL →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
